Gadoleic acid

Synopsis

Gadoleic Acid: A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Names and Classification

Gadoleic acid, also known as cis-9-eicosenoic acid, bears the IUPAC name (Z)-icosa-9-enoic acid and has the molecular formula C₂₀H₃₈O₂. It is a monounsaturated fatty acid with 20 carbon atoms and a single cis double bond in position 9. Its common name is derived from a combination of the genus for cod (Gadus) and the Latin word oleum (oil), which is itself derived from the Ancient Greek ἔλαιον (elaion), meaning olive oil.

The compound has one cis double bond, reckoned from the methyl end in the omega-11 (ω-11) or n-11 position, expressed in shorthand as 20:1n-11. It is a member of the sub-group called very long chain fatty acids (LCFA), namely fatty acids with 20 or more carbon atoms.

An important terminological nuance exists in the literature. Eicosenoic acid is a long-chain monounsaturated fatty acid (C20:1). The trivial names for the 9-cis and 11-cis isomers are gadoleic acid and gondoic acid, respectively. Despite this distinction, some sources and databases use "gadoleic acid" and "gondoic acid" interchangeably, particularly when referring to the C20:1 component of jojoba oil. The authoritative biochemical designation of the marine-sourced compound — the subject of this article — is the 20:1 n-11 (cis-9) isomer, registered under CAS number 29204-02-2 and PubChem CID 5282767.

Recognized synonyms include: cis-gadoleic acid; 9Z-eicosenoic acid; cis-9-icosenoic acid; cis-9-eicosenoic acid; (Z)-eicos-9-enoic acid; (Z)-icos-9-enoic acid; and the shorthand designations C20:1C and C20:1n-11.

1.2 Physical and Chemical Properties

Gadoleic acid has a molecular weight of 310.51452 g/mol and the IUPAC name (Z)-icos-9-enoic acid. In purified form, its melting point is 23–23.5 °C (73.4–74.3 °F) and its boiling point is 170 °C (338 °F) at 0.1 mmHg. It is a colorless to pale yellow liquid at room temperature and is insoluble in water but soluble in organic solvents.

Fatty acids such as gadoleic acid are essential for cell signaling, production of energy, and modulation of membrane fluidity as critical components of cell membranes. The presence of the double bond imparts fluidity to lipid membranes, making it important in biological systems.

1.3 Discovery and Historical Identification

Gadoleic acid, a carboxylic acid with a 20-carbon chain, was discovered in cod liver oil by Bull H. in 1906, while the structure was clarified by Takano M. in 1933. Its identification in cod liver oil established it as one of the earlier recognized very long chain fatty acids in marine lipids.

2. Natural Sources and Occurrence

2.1 Marine Animal Sources

Most plants and algae cannot build fatty acids with more than 18 carbons, but many marine animals can elongate oleic acid to form gadoleic acid (C20:1n-9) and various 22- and 24-carbon fatty acids. Gadoleic acid is common in the lipids of many kinds of fish, especially those living at high latitudes.

It occurs as a glycerol ester in fish — where it originates from dietary crustacean — such as cod, shark, and ray, or their liver oils. Saury, pollock, herring, capelin, and sprats, as well as marine mammals such as seals and whales, are all enriched in long-chain monounsaturated fatty acids that originate from their food source, such as zooplankton. Gadoleic acid is among the principal long-chain monounsaturated fatty acids found within these marine lipid pools.

In fish oil, monounsaturated fatty acids present alongside DHA and EPA include myristoleic acid (14:1 ω-5), palmitoleic acid (16:1 ω-7), oleic acid (18:1 ω-9), eicosenoic acid (20:1 ω-9), gadoleic acid (20:1 ω-11), and erucic acid (22:1 ω-9).

2.2 Plant-Derived Sources

Gadoleic acid, as well as in cod liver oil and other fish that feed on crustaceans, is present in the triglycerides and cyanolipids of some Sapindaceae of the genus Paullinia. In small quantities it is also present in rapeseed oil, pumpkin seed oil, and sesame seed oil.

Among plant sources, jojoba (Simmondsia chinensis) is of particular note. Fatty acid profiles in jojoba oil vary significantly depending on the jojoba genotype. Gadoleic acid exhibits the highest percentage value (67.85–75.50%) in extracted jojoba oil, followed by erucic acid (12.60–14.81%) and oleic acid (7.86–10.99%). Jojoba oil is the only unsaturated liquid wax extracted from plant sources in large quantities, and has a chemical composition similar to sperm whale oil.

Gadoleic acid also appears at lower concentrations in the oils of morama beans (Tylosema esculentum). The lipid of morama beans is mainly (~75%) unsaturated fatty acids, with the principal fatty acid being oleic acid (43%); the beans furthermore contain gadoleic acid, among other fatty acids, in lower concentrations.

2.3 Other Biological Sources

Gadoleic acid (20:1 n-11) has also been detected, alongside gondoic acid (20:1 n-9) and nervonic acid (24:1), when certain bacteria such as Lactobacillus johnsonii N6.2 are cultivated in media containing erucic acid as the sole source of fatty acid. This finding suggests that some gut-associated bacteria are capable of metabolizing or producing gadoleic acid precursors under specific nutritional conditions, though the significance of this in vivo remains uncharacterized.

3. Traditional and Historical Use

3.1 Norse and Nordic Traditions

Gadoleic acid is not a substance that was known or isolated in traditional medicine; it was only chemically identified in the early twentieth century. Its historical significance is therefore inseparable from the fish oils — most notably cod liver oil — in which it naturally occurs as one of several fatty acid constituents.

The origin of the use of cod liver oil as a food dates back to the Viking Era (late 700s to 1100 CE). Fish and fish liver oil were important parts of the Norse diet. The Vikings consumed most of the fish liver oil during the cold months when the days were shorter and lacked sunlight.

Fish liver oils have been used as far back as the Middle Ages, and populations in Scandinavia have used them for thousands of years. The Norse name for cod liver oil is lysi, meaning "light," and it was used to fuel lamps all over Europe. It also provided nutritional energy, essential fatty acids, and fat-soluble vitamins to the public. It was, for example, mixed with tallow to make a soft spread that could replace butter as a spread on dried fish and bread.

Centuries ago, northern Europeans used cod liver oil to protect them from the cold. It was made from the livers of Gadus morhua and other species of cod. Cod liver oil was said to relieve such complaints as rheumatism, aching joints, and stiff muscles.

3.2 Indigenous Arctic Cultures

Dating back to a time so distant that it is likely difficult to document, fat from the livers of cod and other fish species was used for illumination and heating. Both the Sámi people and the Inuit used fish and seal oil for light and warmth, and from the Middle Ages, the oil became commonly used as lamp oil by other Europeans as well.

3.3 Medicinal Use from the 18th Century Onward

The earliest documented use of cod liver oil for medicinal purposes dates back to 1789, when a doctor in Manchester used cod liver oil as a remedy for rheumatism. It was also suggested by doctors in 1824 as a treatment for rickets, a deficiency disease caused by a lack of vitamin D.

At the beginning of the 20th century, scientists established that cod liver oil was antirachitic, and it became commonplace for mothers to give it to their children. As scientific analysis of cod liver oil matured through the 19th and 20th centuries, the full complement of its fatty acid constituents — including gadoleic acid — was progressively elucidated.

The latter half of the 1900s saw a boom in the development of industrial processing of cod liver oil. Filtration, concentration, deodorisation, winterisation, alkali treatments, and chemical alteration were all done in one way or another to make the product more palatable, economic, and aesthetically pleasing. To speed up the separation of oil from the livers, the livers would be heated (sometimes under pressure). To increase the concentration of omega-3 fatty acids, they would be chemically converted into ethyl esters.

3.4 Traditional Use of Jojoba Oil

Among plant-derived sources of gadoleic acid, jojoba oil also carries a documented history of traditional use. Centuries ago, Native Americans were already using jojoba oil for its curative, beautifying (skin, hair), artisanal (candle making), and nutritional properties, including as a beverage similar to coffee.

4. Key Constituents, Biochemistry, and Mechanisms of Action

4.1 Position in Lipid Biochemistry

Gadoleic acid (20:1n-11) belongs to the class of long-chain monounsaturated fatty acids (LCMUFA). LCMUFA are defined as monounsaturated fatty acid isomers with aliphatic tails of at least 20 carbons, with n-11 LCMUFA as the most abundant marine-derived component. Within the cell, long-chain fatty acids are found in phospholipids, triglycerides, and cholesterol esters, where they influence membrane architecture and energy storage.

4.2 Biosynthesis: The Elongase Pathway

Gadoleic acid is produced biologically via chain elongation of shorter monounsaturated fatty acids. Most plants and algae cannot build fatty acids with more than 18 carbons, but many marine animals can elongate oleic acid to form gadoleic acid (C20:1n-9) and various 22- and 24-carbon fatty acids. This reaction is catalyzed by the fatty acid elongase (ELOVL) family of enzymes. ELOVLs are membrane-embedded enzymes that elongate very long chain fatty acids, precursors of sphingolipids and ceramides.

The very-long-chain fatty acid elongase (ELOVL) family plays essential roles in lipid metabolism and cellular functions. This family encompasses structural characteristics, functional properties, and physiological significance across individual ELOVL isoforms, providing insights into lipid biosynthesis, cell membrane dynamics, and signaling pathways.

4.3 Membrane Fluidity

Fatty acids are essential for cell signaling, production of energy, and modulation of membrane fluidity as critical components of cell membranes. Deficiency in certain fatty acids is detrimental to normal cellular health and causes many human diseases. Gadoleic acid, by virtue of its 20-carbon chain and single cis double bond, contributes to membrane fluidity through its presence in phospholipid bilayers. By incorporating very long chain fatty acids into membrane lipids, elongase enzymes influence membrane properties and contribute to cellular homeostasis. Very long chain fatty acids are known to increase membrane rigidity and stability.

4.4 Interaction with the p53 Tumor Suppressor Protein

A notable in-vitro mechanistic finding has been reported by Iijima et al. (2006): gadoleic acid is a monounsaturated fatty acid that inhibits the double-stranded DNA (dsDNA) binding activity of p53 when used at a concentration of 1.2 nM. The tumor suppressor protein p53 is a critical transcription factor involved in regulating numerous cellular processes. A role for the p53 protein in regulating lipid and lipoprotein metabolism has been identified — a process not yet previously conceived as related to p53, which is known mainly for its tumor-suppressive functions. The physiological implications of gadoleic acid's inhibitory effect on p53 DNA-binding at nanomolar concentrations are not yet fully elucidated, and no human studies have examined this mechanism.

4.5 Hepatic Lipid Metabolism

Hepatic levels of gadoleic acid are reduced in rats fed a high-fat or a high-fat high-cholesterol diet, and are increased in rats fed a high-cholesterol diet. This observation, reported in a lipidomics study by Serviddio et al. (2016), suggests that hepatic gadoleic acid levels are dynamically regulated in response to dietary fat and cholesterol loading. The mechanisms linking gadoleic acid availability to hepatic lipid homeostasis remain an area of preclinical investigation.

4.6 Role as a Component in Complex Marine Lipid Mixtures

Gadoleic acid in foods is virtually never consumed as an isolated compound. In fish oils and natural plant oils, it co-occurs with a broad array of fatty acids, vitamins, and other bioactive lipids. Potential mechanisms whereby n-3 polyunsaturated fatty acids may reduce risk for cardiovascular disease include their beneficial effects on lipid and lipoprotein metabolism, blood pressure, platelet function, arterial cholesterol delivery, vascular function, and inflammatory responses. The extent to which gadoleic acid independently contributes to, modulates, or opposes these effects is not well characterized in isolation.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health

Regular fish and fish oil consumption is widely recommended for protection against cardiovascular diseases (CVD). Fish and other marine life are rich sources of the cardioprotective long-chain n-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The lipid content and fatty acid profile of fish, however, vary greatly among different fish species. In addition to n-3 PUFA, certain fish such as saury, pollock, and herring also contain high levels of long-chain monounsaturated fatty acids (LCMUFA), with aliphatic tails longer than 18 carbon atoms.

Compared with the well-studied n-3 PUFA, limited information is available on the health benefits of marine-derived LCMUFA, particularly with regard to CVD. Current research has sought to summarize the current knowledge and provide perspective on the potential therapeutic value of dietary LCMUFA-rich marine oil for improving CVD risk factors.

Congestive Heart Failure: The most directly relevant human epidemiological data on gadoleic acid and cardiovascular disease comes from analyses of the Cardiovascular Health Study (CHS) and the Atherosclerosis Risk in Communities Study (ARIC). In the 1960s–1980s, feeding experiments in rodents, pigs, and non-human primates suggested that consumption of erucic acid (22:1n9) and cetoleic acid (22:1n11) caused cardiac steatosis. Although potential effects in humans were never studied, mechanistic studies suggest that exposure to long-chain monounsaturated fatty acids (LCMUFA, including 20:1, 22:1, and 24:1 fatty acids) might impair the myocardium.

After excluding participants with prevalent congestive heart failure (CHF), the CHS and ARIC analyses included 3,694 and 3,577 participants, respectively. Methods for assessing plasma phospholipid fatty acids in the two cohorts slightly differed. In CHS, 42 known individual fatty acids were quantified; in ARIC, 29 fatty acids. The study evaluated LCMUFA as the main exposure variables: gadoleic acid (20:1), erucic acid (22:1), and nervonic acid (24:1).

Two epidemiologic studies showed that higher circulating erucic acid, but not gadoleic acid, were significantly correlated with higher incident congestive heart failure in the population from the Cardiovascular Health Study (CHS) and the Atherosclerosis Risk in Communities Study, Minnesota subcohort (ARIC). Higher circulating levels of 22:1 and 24:1, with apparently diverse dietary sources, were associated with incident CHF in two independent cohorts, suggesting possible cardiotoxicity of these LCMUFA in humans. Gadoleic acid (20:1) was not independently implicated in this signal.

The majority of LCMUFA examined in the observational studies were n-9 LCMUFA, which are generally found in both healthful and unhealthful food sources, such as fish, mustard, vegetable oils, and processed meats. Furthermore, in addition to LCMUFA, serum levels of some other fatty acids also changed in these observational studies, thus making it difficult to elucidate the exact relationship between LCMUFA intake and CVD risk.

One ScienceDirect overview note cites — attributing to the Handbook of Lipids in Human Function (2016) — that gadoleic acid (C20:1 n-9) is a monounsaturated fatty acid that has been found to have a detrimental association with coronary heart disease (CHD), as indicated by a relative risk increase in certain studies. It is important to emphasize that this claim conflates the n-9 and n-11 isomers, and that the primary human prospective data reviewed above did not isolate gadoleic acid as an independent risk factor for CHF separate from erucic acid and nervonic acid. The evidence in this area is limited, based on observational data, and subject to significant confounding.

Evidence strength summary (cardiovascular): Preliminary, based on animal models and observational epidemiological cohort data. No randomized controlled trials (RCTs) or interventional studies have examined gadoleic acid as an isolated exposure. Confounding by co-occurring fatty acids and dietary patterns is a major limitation.

5.2 Lipid Metabolism and Liver Biology

Gadoleic acid is studied for its role in lipid metabolism and its potential impact on the physical properties of cell membranes. The only direct experimental data in vivo comes from rodent models. As noted above, hepatic gadoleic acid levels shift in response to high-fat and high-cholesterol diets in rats, suggesting a dynamic role in hepatic lipid partitioning. All available evidence in this domain is preclinical (animal and in-vitro). No human clinical trials have examined gadoleic acid's effect on lipid metabolism as an isolated variable.

5.3 Interaction with p53 and Potential Oncological Relevance

The in-vitro inhibitory effect of gadoleic acid on p53's DNA-binding activity, observed at 1.2 nM by Iijima et al. (2006), situates gadoleic acid within the growing literature on fatty-acid regulation of transcription factors. p53 has been found to augment the activity of secreted phospholipid transfer protein (PLTP), which plays a major role in lipoprotein biology and atherosclerosis pathology. These findings expose another facet of p53 functions unrelated to tumor suppression and render it a novel regulator of hepatic lipid metabolism and consequently of systemic lipid homeostasis and atherosclerosis development.

The potential implications of gadoleic acid's p53 inhibition — whether relevant to tumor suppression, metabolic regulation, or neither at physiological concentrations — remain entirely speculative. No human or animal studies have examined this mechanism in the context of cancer or lipid disease endpoints. Evidence strength: Single in-vitro study only; no translational or clinical data.

5.4 Monounsaturated Fatty Acid Class Effects and Type 2 Diabetes

Gadoleic acid has not been studied individually in the context of glucose metabolism or diabetes. However, as a MUFA, it belongs to the broader fatty acid class that has been the subject of clinical investigation. Dietary interventions in patients with type 2 diabetes are important for preventing long-term complications. Although a healthy diet is crucial, there is still uncertainty about the optimal macronutrient composition. Meta-analyses have been performed comparing diets high in cis-monounsaturated fatty acids (MUFA) to diets high in carbohydrates or in polyunsaturated fatty acids on metabolic risk factors in patients with type 2 diabetes. Extrapolating any such class-level findings to gadoleic acid specifically is not scientifically warranted without dedicated studies.

5.5 Skin Biology and Cosmetic Applications

Gadoleic acid, particularly as delivered through jojoba oil, is a subject of research interest in dermatology and cosmetic science. Gadoleic acid represents the main fatty acid in jojoba seed oil. It is similar to human sebum, which acquires high absorption in the human skin and can therefore moisturize the skin without a greasy effect. The chemical composition of jojoba oil is very similar to that of human sebum. This vegetable oil contains nearly 80% monounsaturated fatty acids including erucic acid, oleic acid, and gadoleic acid, as well as ceramides. The skin readily absorbs this vegetable oil, which strengthens the hydrolipidic film and regulates sebum flow.

It is important to note that these properties are attributed to jojoba oil as a whole formulation, not to gadoleic acid as an isolated active ingredient. No clinical trials have examined purified gadoleic acid as a topical or oral intervention for any dermatological condition.

5.6 Marine Physiology and Adaptation

Gadoleic acid is used in studies focusing on the lipid composition of marine organisms and how it influences their physiology and adaptation to different environments. At high latitudes, cold-water fish accumulate higher proportions of long-chain MUFAs, including gadoleic acid, possibly as an adaptation to maintain membrane fluidity at low temperatures. This represents an area of ecological and biochemical research rather than human health intervention.

6. Body Systems and Health Areas of Association

Cardiovascular system: Gadoleic acid is measurable in circulating plasma phospholipids and has been studied in the context of CVD risk via epidemiological cohort analyses. It is associated with fish and fish oil consumption. Unlike its longer-chain analogue erucic acid (22:1), circulating gadoleic acid was not independently associated with incident congestive heart failure in two major prospective cohort studies.
Hepatic/metabolic system: Preclinical lipidomics data indicate that hepatic gadoleic acid concentrations are diet-sensitive in rodents, rising with high-cholesterol feeding and falling with high-fat feeding. The relevance in human hepatic pathology has not been established.
Cell biology/membrane biology: As a very long chain MUFA, gadoleic acid contributes to the phospholipid composition of biological membranes and is studied for its effects on membrane fluidity and cellular function.
Genomics/transcription factor biology: In vitro evidence demonstrates inhibitory activity against p53 DNA-binding at nanomolar concentrations. The physiological and pathological consequences of this have not been investigated in vivo.
Integumentary system: As the dominant fatty acid in jojoba oil (67–75%), gadoleic acid is present in preparations used topically for skin moisturization and hair care, attributed in part to the structural similarity of jojoba oil to human sebum.
Reproductive/marine biology: LCMUFA including gadoleic acid play recognized roles in the lipid profiles of marine organisms and their adaptation to cold-water environments.

7. Dosage Forms and Reported Dosages

Gadoleic acid is not available, regulated, or standardized as a stand-alone dietary supplement in any jurisdiction reviewed. It is consumed as part of natural food sources and oil preparations. No clinical or interventional study has examined a defined oral dose of isolated gadoleic acid in humans. The following reflects reported composition data only:

Jojoba oil (topical/oral wax ester): Gadoleic acid accounts for 67.85–75.50% of extracted jojoba oil by weight across genotypes studied. Jojoba oil is typically used topically and is not commonly ingested as a food oil, given that it is technically a liquid wax ester.
Fish oils (cod liver oil and related products): Gadoleic acid is one of multiple monounsaturated fatty acids present in cod liver oil and related products at levels that vary by species, processing method, and season. Cod liver oil delivers a range of fatty acids besides omega-3s. In a teaspoon of cod liver oil, saturated and monounsaturated fats are found, similar to those in extra virgin olive oil and avocados. No specific percentage for gadoleic acid alone in commercial cod liver oil preparations was reported in the peer-reviewed sources reviewed.
Research context: The in-vitro study by Iijima et al. (2006) demonstrated p53 DNA-binding inhibition at a gadoleic acid concentration of 1.2 nM — a concentration context that is not directly translatable to any dietary or supplemental dose in humans.

No human clinical trial has established, studied, or reported a therapeutic or supplemental dose range for gadoleic acid as an isolated compound.

8. Safety Considerations and Interactions

8.1 Gadoleic Acid and Cardiotoxicity: Dissociation from Erucic Acid

Much of the historical concern about LCMUFA and cardiac safety derives from animal studies on erucic acid (C22:1n-9) and cetoleic acid (C22:1n-11). Decades-old animal experiments suggested dietary long-chain monounsaturated fatty acids caused cardiotoxicity, leading, for example, Canada to develop Canadian-oil-low-in-erucic-acid (Canola) from rapeseed. However, potential cardiotoxicity in humans and contemporary dietary sources of LCMUFA remained unknown.

Importantly, the human epidemiological data have not implicated gadoleic acid (20:1) in cardiac harm. Two epidemiologic studies showed that higher circulating erucic acid, but not gadoleic acid, were significantly correlated with higher incident congestive heart failure in the CHS and ARIC populations. This distinction is scientifically meaningful: erucic acid and gadoleic acid are structurally different (22 vs. 20 carbons; n-9 vs. n-11 position in the marine isomer), and they appear to differ in their cardiovascular risk associations in epidemiological data.

8.2 Confounding in Epidemiological Data

The majority of LCMUFA examined in observational studies were n-9 LCMUFA, generally found in both healthful and unhealthful food sources, such as fish, mustard, vegetable oils, and processed meats. Furthermore, serum levels of other fatty acids also changed in these observational studies, making it difficult to elucidate the exact relationship between LCMUFA intake and CVD risk. This confounding severely limits the ability to draw conclusions about gadoleic acid's safety profile from existing epidemiological data.

8.3 High-Dose Animal and Preclinical Data

In the 1960s–1980s, feeding experiments in rodents, pigs, and non-human primates suggested that consumption of erucic acid (22:1n9) and cetoleic acid (22:1n11) caused cardiac steatosis. Although potential effects of LCMUFA in humans were never studied, mechanistic studies suggest that exposure to long-chain monounsaturated fatty acids (LCMUFA, including 20:1, 22:1, and 24:1) might impair the myocardium. The inclusion of 20:1 species (which includes gadoleic acid) in this mechanistic category is noted in the literature, but human data do not support an equivalent clinical risk signal for gadoleic acid as for its 22-carbon relatives.

8.4 Absence of Established Tolerable Daily Intake

Unlike erucic acid (22:1), for which EFSA and Food Standards Australia have established safety guidance, no regulatory body has established a specific tolerable daily intake, acceptable daily intake, or upper limit for gadoleic acid as an isolated compound. This reflects both the relatively low dietary exposure to gadoleic acid as an isolated substance and the absence of dedicated human toxicological studies. Safety data are effectively derived from the overall safety record of foods in which gadoleic acid naturally occurs — principally fish oils and jojoba oil.

8.5 In-Vitro p53 Inhibition: Significance Unknown

The inhibition of p53 dsDNA-binding activity by gadoleic acid at 1.2 nM, observed in an in-vitro cell-free system, has not been reproduced in intact cell studies, animal models, or human subjects. Whether this interaction is relevant at physiological tissue concentrations achieved through dietary intake is unknown. The observation should not be interpreted as a defined adverse or beneficial effect without substantially more experimental evidence.

8.6 Interactions with Pharmaceutical Agents

No peer-reviewed clinical studies or case reports were identified in the sources reviewed that describe pharmacokinetic or pharmacodynamic interactions between gadoleic acid and any pharmaceutical drug. Given that gadoleic acid is consumed predominantly as a minor component of fish oils and plant oils, any interactions would be difficult to distinguish from those of co-occurring fatty acids such as EPA and DHA.

9. Current Research Status and Knowledge Gaps

Gadoleic acid remains a comparatively understudied compound relative to better-characterized fatty acids such as EPA, DHA, oleic acid, and even erucic acid. Compared with the well-studied n-3 PUFA, limited information is available on the health benefits of marine-derived LCMUFA, particularly in regard to CVD. EPA and DHA represent just two members of a much larger fatty acid family found in fish and fish oil. Most of these other fatty acids have not been extensively researched yet.

The primary areas requiring further research include: (1) dedicated human interventional studies with gadoleic acid as an isolated exposure; (2) clarification of its independent cardiovascular risk or benefit profile, separated from the longer-chain LCMUFA; (3) characterization of the in-vivo significance of p53 DNA-binding inhibition; (4) mechanistic studies of hepatic gadoleic acid metabolism in human subjects; and (5) standardization of gadoleic acid content in commercial fish oil and jojoba oil preparations.